Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients

British Journal of Cancer

Volumn 78, Issue 3, 1998, Pages 328-335

  Larsson, R ^a   Dhar, S ^a   Ehrsson, H ^b   Nygren, P ^a   Lewensohn, R ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytotoxicity assay; Drug resistance; Human tumour cell; L prolyl m L sarcolysyl L p fluorophenylalanine; Melphalan

Indexed keywords

GLUTATHIONE; MELPHALAN; OLIGOPEPTIDE; PEPTICHEMIO; PHENYLALANINE DERIVATIVE; SARCOLYSIN;

ARTICLE; CONJUGATION; COVALENT BOND; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE;

EID: 0031871208     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.494     Document Type: Article

References (37)

1. Batist G, Torres S, Demuys JM, Greene D, Lehnert S, Rochon M and Panasci L (1989) Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line. Mol Pharmacol 36: 224-230
2. Bellamy WT, Dalton WS, Gleason MC, Grogan TM and Trent JM (1991) Development and characterisation of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51: 995-1002
3. Botling J, Liminga G, Larsson R, Nygren P and Nilsson K (1994) Development of vineristine esistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without over expression of the 170 kDa P-glycoprotein. Int J Cancer 58: 269-214
4. Cole S, Bhardwaj G, Gerlach JH, Almquist KC and Deeley RG (1992) A novel ATP binding cassette transporter gene overexpressed in multidrug resistant human lung tumor cells. Science 268: 1650-1654
5. Csoka K, Larsson R, Tholander B, Gerdin E, De La Torre M and Nygren P (1994) Cytotoxic drog sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54: 163-170
6. Csoka K, Liliemark J, Larsson R and Nygren P (1995) Evaluation of the cytotoxic activity of Gemcilabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22: 47 53
7. Dalton WS, Durie BG, Alberts DS, Gerlach JH and Cress AE (1986) Characterisation of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46: 5125-5130
8. Danks MK, Yalowich JC and Beek WT (1987) Atypical multidrug resistance in a human leukeimc cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297-1301
9. Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869
10. De Barbieri A (1972) Peptichemio: a synthesis of pharmacological, morphological. biochemical and biomolecular investigations. In: Proceedings of the Symposium on Peptichemio. Milan 18: 13-59
11. Dhar S, Nysgren P, Csoka K, Botling J, Nilsson K and Larsson R (1996) Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 74: 888-896
12. Ehrsson H, Lewensohn R, Wallin I, Hellström M, Merlini G and Johansson B (1993) Pharmacokinetics of peptichemio in myeloma patients: release of M-L-sarcolysin in vivo and in vitro. Cancer Chemother Pharmacol 31: 265-268
13. Fridborg H, Nygren P, Dhar S, Csoka K, Kristensen J and Larsson R (1990) In vitro evaluation of new anticancer drugs, exemplified by vinorelbine. using the flourometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. J Expt Ther Oncol 1: 286-295
14. Gingold N, Pitterman E and Stacher A (1974) Peptichemio in the therapy of malignancies (phase-1-study). The evaluation committee. Int J Clin Pharmacol Biopharm 110: 190-202
15. Hansson J, Lewensohn R, Ringborg U (1991) Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-Sarcolysin in human melanoma cells. Anticancer Res 11: 1725-1730
16. Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA and Bodey GP (1980) A phase II study of Peptichemio in advanced breast cancer. Cancer 45: 2524-2528
17. Jonsson E, Fridborg H, Csoka K, Dhar S, Sundström C, Nygren P and Larsson R (1997) Cytotoxic activity of Toptecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76: 211-219
18. Larsson R and Nygren P (1994) Cytotoxic activity of topoisomerase II inhibitors in primary cultures of human tumour cells from patients with human hematologic and solid tumors. Cancer 74: 2857-2862
19. Larsson R, Kristensen J, Sandberg C and Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185
20. Larsson R, Fridborg H, Liliemark J, Csoka K, Kristensen J, De La Torre M and Nygren P (1994) In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human hematological and solid tumors. Eur J Cancer 30A: 1022-1026
21. Lewensohn R, Ehrsson H, Hansson J and Ringborg U (1991a) Increased toxicity and DNA cross-linking by peptide bound m-L-Sarcolysin (Peptichemio) as compared to melphalan and m-L-Sarcolysin in human melanoma cell lines. Anticancer Res 11: 321-324
22. Lewensohn R, Hernberg JO, Ehrsson H and Merlini G (1991b) Efficacy of peptide bound m-L-sarcolysin (Peptichemio) on melphalan resistant human myeloma cells in vitro. Med Oncol Tumor Pharmacother 8: 265-269
23. Merlini G, Gobbi GP, Riccardi A, Riva G, Sardi C and Perugini S (1982) Peptichemio induction therapy in myelomatosis. Cancer Chemother Pharmacol 8: 9-16
24. Mirski SE, Gerlach JH and Cole SP (1987) Multidrug resistance in a human small cell cancer cell line selected in adriamycin. Cancer Res 47: 2594-2598
25. Mulcahy RT, Bailey HH and Gipp JJ (1994) Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 4: 67-71
26. 2+ concentration. Biosci Rep 10: 231-237
27. Nygren P, Kristensen J, Sundström C, Lönnerholm G, Kreuger A and Larsson R (1992) Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6: 1121-1128
28. Nygren P, Fridborg H, Csoka K, Sundström C, De La Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, Tholander B and Larsson R (1994) Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56: 715-720
29. Nygren P, Csoka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin O, Tholander B, Kreuger A, Lönnerholm G, Jakobsson Å, Olsen L, Kristensen J and Larsson R (1995) The cytotoxic activity of Taxol in primary cultures of tumor cells from patients is partly mediated by Cremophore EL. Br J Cancer 71: 478-481
30. Paccagnella A, Tredese F, Salvagno L, Brandes A, Sileni VC, Daniele O, Fornasiero A, Fosser V, Nicoletto O, Maggino T and Florentino MV (1985) Peptichemio in pretreated patients with ovarian cancer. Cancer Treat Rep 69: 17-20
31. Paccagnella A, Salvagno L, Chiarion-Sileni II V, Boiznella S, De Besi P, Frizzarin M. Pappagallo GL, Fosser VP, Fornasiero A, Segati R and Florentino MV (1986) Peptichemio in pretreated patients with plasma cell neoplasms. Eur J Cancer Clin Oncol 22: 1053-1058
32. Perugini S, Bobbio PE, Ghizzi A, Riccardi A, Martinotti A and Merlini P (1976) Peptichemio in the treatment of plasma cell leukemia. Haematologica 61: 248-249
33. Stern K, Birmingham MK, Cullen A and Richer R (1951) Peptidase activity in leucocytes, erythrocytes and plasma of young adult and senile subjects. J Clin Invest 30: 84-89
34. Weisenthal LM, Dill P and Birkhofer M (1991) Accurate identification of disease-specific activity of antineoplastic agents with an in vitro fresh tumor assay measuring killing of largely non-dividing cells. Proc Am Assoc Cancer Res 32: 384
35. Yagi MJ, Bekesi JG, Daniel MD, Holland JF and De Barbieri A (1984) Increased cancericidal activity of PTT. 119. a new synthetic bis-(2-chloroethyl )amino-1 -phenylalanine derivative with carrier amino acids. Cancer Chemother Pharmacol 12: 70-76
36. Yagi MJ, Scanlon KJ, Chin SE, Holland JE and Bekesi JG (1988) Multiple transport pathways for L1210 cells: uptake of PTT. 119, a bifunctional alkylator with carrier amino acids. Chemotherapy 34: 235-247
37. Zaniboni A, Simoncini E, Marpicati P, Montini E, Rossi G and Marini G (1988) Peptichemio, teniposide and high-dose dexamethasone: a neu active combination for relapsing and refractory multiple myeloma. A pilot study. Anticancer Res 8: 125-128